Molecular and Clinical Epidemiology of CXCR4‐Using HIV‐1 in a Large Population of Antiretroviral‐Naive Individuals
about
HIV-1 entry inhibitors: an overviewPractical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial reviewHIV-1 entry inhibitors: recent development and clinical useClinical significance of HIV-1 coreceptor usage.Bioinformatic analysis of HIV-1 entry and pathogenesis.Access denied? The status of co-receptor inhibition to counter HIV entryMaraviroc: the evidence for its potential in the management of HIVCharacterization of partial and near full-length genomes of HIV-1 strains sampled from recently infected individuals in São Paulo, BrazilPlasma Metabolomics Biosignature According to HIV Stage of Infection, Pace of Disease Progression, Viremia Level and Immunological Response to TreatmentHIV-1 drug resistance and resistance testing.Peptide and protein-based inhibitors of HIV-1 co-receptorsFrequent detection of CXCR4-using viruses among Brazilian blood donors with HIV-1 long-standing infection and unknown clinical stage: Analysis of massive parallel sequencing dataX4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process.HIV-1 subtype and viral tropism determination for evaluating antiretroviral therapy options: an analysis of archived Kenyan blood samplesCharacterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individualsLimited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapyAnti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.Tropism testing in the clinical management of HIV-1 infection.Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques.Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infectionRecurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infectionsThree-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population.Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infectionHIV-1 antiretroviral resistance: scientific principles and clinical applicationsCo-receptor usage and prediction of V3 genotyping algorithms in HIV-1 subtype B' from paid blood donors experienced anti-retroviral therapy in Chinese central province.Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults.CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.Analysis of the CCR5 gene coding region diversity in five South American populations reveals two new non-synonymous alleles in Amerindians and high CCR5*D32 frequency in Euro-Brazilians.Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.The neuropathogenesis of feline immunodeficiency virus infection: barriers to overcomeThe number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study.Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.A diagnostic HIV-1 tropism system based on sequence relatedness.Clinical use of CCR5 inhibitors in HIV and beyondSelected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage.Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study.Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS.Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
P2860
Q24645525-C080E4C3-F555-4D1F-871D-F9CB1C928924Q26853055-258E8D2C-D7CD-4735-BB80-2AF4065DCF77Q27003887-AA4AF3F5-2E4F-4D6F-ADB7-78521BC40D0BQ27691426-20DB0946-B3C1-4708-8000-CA18657F790AQ27693321-CD6064FF-38F0-40A8-A34C-6F6CD08368C5Q28300187-869C91AF-C9F1-4B1E-B681-89815828DC65Q28476655-EA6FB4A2-7724-44A6-A1CE-64D32B5E587AQ28477491-51BEF299-6301-4781-AEFD-0452508AF5E0Q28587923-2330F9A0-54D7-462D-ADC5-F7EE8B618907Q30245693-1D2BBA2B-AF03-4AD1-B357-4A0E7D1DA974Q30352117-03D7C677-111C-4761-8306-DE6919B73428Q31044033-14F7A04E-F810-4DA0-A236-581507A5F2A5Q31117473-0D986828-A2DB-4CBD-A3CD-416ACD98DF70Q33521125-0F2239C7-FAD3-492C-AF34-D8C943B11435Q33685141-96388B48-6B67-48D8-8887-134850A392C8Q33721466-2FC68727-C495-449F-938B-A21502291C86Q33798442-D9848B16-5E63-49EC-BD43-9C735CBF7866Q33869686-44411B47-B4BB-4A77-8A08-9AF61A62F036Q33961448-558C7185-CC26-4E18-A4AF-B779CF467A01Q33973857-E45A9722-B6C1-4C80-8FAC-FE26EE26F184Q34042642-50144949-C541-4E65-9A95-18937399EDC2Q34051325-5AF23D52-C7B8-4D82-AB24-2D8777010B25Q34098010-B659BFB2-849E-49D2-8B1B-5C479A51F507Q34150882-C77F4BCA-BD9C-416F-B7BC-CA6CDC8F2CDCQ34190296-F0C61116-B417-4929-958B-6B755A5FD64AQ34280466-B747039F-73D9-4BC1-8C8F-314D59B2804DQ34332104-FE940D01-ED97-46D1-A656-7192766645F3Q34437126-BA26EEB9-4960-485E-8CAC-C252EE96AE86Q34473072-40A6C74D-774E-49DD-8504-2BF102F384C1Q34548491-5AE92CA3-AAD5-42F0-B8A9-029B05CEA8D4Q34623149-AA1168E2-A30B-4F79-8391-37FE2CD85502Q34634294-E667640D-FEC6-40F2-A893-7E59AC3A75F8Q34740235-7CEF399C-EA90-4928-A3DE-869EAABCD065Q34846620-283F41D9-289A-4301-8F20-BFE5F6A8486CQ34983107-2FA46CC0-4F93-42D6-81AA-CE25BC4C98F5Q35018145-68BDF4AE-B807-471E-8F4B-5B639414D68AQ35052934-846C4202-BD5D-4990-B576-21B010C67349Q35071940-CF141677-D82E-4EEC-9D94-D074571B62D9Q35274968-9870299B-3BB8-448C-B7F8-5073300FA36FQ35441620-2059B2E1-FCFC-4188-8D92-EE4F91F3A0DF
P2860
Molecular and Clinical Epidemiology of CXCR4‐Using HIV‐1 in a Large Population of Antiretroviral‐Naive Individuals
description
article
@en
im August 2005 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2005
@uk
name
Molecular and Clinical Epidemi ...... tiretroviral‐Naive Individuals
@en
Molecular and Clinical Epidemi ...... tiretroviral‐Naive Individuals
@nl
type
label
Molecular and Clinical Epidemi ...... tiretroviral‐Naive Individuals
@en
Molecular and Clinical Epidemi ...... tiretroviral‐Naive Individuals
@nl
prefLabel
Molecular and Clinical Epidemi ...... tiretroviral‐Naive Individuals
@en
Molecular and Clinical Epidemi ...... tiretroviral‐Naive Individuals
@nl
P2093
P50
P356
P1476
Molecular and Clinical Epidemi ...... tiretroviral‐Naive Individuals
@en
P2093
Brian Wynhoven
Chanson J. Brumme
Howard B. Mayer
James Goodrich
Jerome J. Asselin
P. Richard Harrigan
Peter K. Cheung
Zabrina L. Brumme
P304
P356
10.1086/431519
P407
P577
2005-08-01T00:00:00Z